These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15331929)

  • 1. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
    Deichmann M; Thome M; Benner A; Näher H
    Oncology; 2004; 66(5):411-9. PubMed ID: 15331929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
    Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
    Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases.
    Deichmann M; Thome M; Benner A; Kirschner M; Hassanzadeh J; Kurzen H
    BMC Cancer; 2005 Jun; 5():58. PubMed ID: 15935100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
    Kirschner M; Helmke B; Starz H; Benner A; Thome M; Deichmann M
    Melanoma Res; 2005 Oct; 15(5):427-34. PubMed ID: 16179870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
    Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
    Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
    Stoehr R; Brinkmann A; Filbeck T; Gamper C; Wild P; Blaszyk H; Hofstaedter F; Knuechel R; Hartmann A
    Oncol Rep; 2004 Jan; 11(1):137-41. PubMed ID: 14654916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of B-RAF and N-RAS mutations in human melanoma.
    Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
    J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma.
    Maat W; Kilic E; Luyten GP; de Klein A; Jager MJ; Gruis NA; Van der Velden PA
    Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):23-7. PubMed ID: 18172070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of BRAF mutations in uveal melanoma.
    Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
    Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
    Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
    Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
    Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
    Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
    Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of exon 15 BRAF germline mutations in familial melanoma.
    Lang J; Boxer M; MacKie R
    Hum Mutat; 2003 Mar; 21(3):327-30. PubMed ID: 12619120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
    Bloethner S; Chen B; Hemminki K; Müller-Berghaus J; Ugurel S; Schadendorf D; Kumar R
    Carcinogenesis; 2005 Jul; 26(7):1224-32. PubMed ID: 15760917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem BRAF mutations in primary invasive melanomas.
    Thomas NE; Alexander A; Edmiston SN; Parrish E; Millikan RC; Berwick M; Groben P; Ollila DW; Mattingly D; Conway K
    J Invest Dermatol; 2004 May; 122(5):1245-50. PubMed ID: 15140228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutations in conjunctival melanoma.
    Gear H; Williams H; Kemp EG; Roberts F
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of constitutively active V599EBRaf.
    Andersen MH; Fensterle J; Ugurel S; Reker S; Houben R; Guldberg P; Berger TG; Schadendorf D; Trefzer U; Bröcker EB; Straten Pt; Rapp UR; Becker JC
    Cancer Res; 2004 Aug; 64(15):5456-60. PubMed ID: 15289355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues.
    Gorden A; Osman I; Gai W; He D; Huang W; Davidson A; Houghton AN; Busam K; Polsky D
    Cancer Res; 2003 Jul; 63(14):3955-7. PubMed ID: 12873990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
    Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT
    Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.